ImmuneWorks
Indianapolis
About ImmuneWorks
ImmuneWorks develops immune tolerance treatments for patients with serious autoimmune diseases in the lung. The company was founded in 2006 to develop safe and effective immune tolerance treatments for patients with serious autoimmune diseases of the lung. The scientific foundation of the company is ImmuneWorks' groundbreaking discovery that antigen-specific autoimmunity is responsible for the disease in over one-half of idiopathic pulmonary fibrosis (IPF) patients. It was incorporated in 2006 and is based in Indianapolis, Indiana.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $735.0K
- Last round: Series Unknown (Dec 2013)
- Website: immuneworks.com
- Phone: (317)278-0205
Industries & Categories
Biotechnology, Health Care
Canonical: https://fsome.com/organization/immuneworks-1916814 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.